

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Canada House Wellness Group Inc.

Trading Symbol: CHV

Number of Outstanding Listed Securities: 250,401,972

Date: November 6, 2019

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On October 1, 2019, Abba Medix Corp, ("Abba) the wholly owned subsidiary of Canada House Wellness Group ("Canada House"), commenced sale of its branded cannabis flower announcing it is available for sale to registered Abba patients. Abba produces handcrafted, premium quality, medical grade cannabis for patients seeking safe solutions for their complex to common health and wellness needs. Currently, Abba has an Indica dominant "Purple Bud" ready for sale. Purple Bud comes from a cross between Jamaican Sativa and Afghani Indica. The flower is named for its purple and lavender hues which offer a piney, sweet aroma of sandalwood.

Abba's 22,000 sq. ft. indoor production facility in Pickering, Ontario, has dried flower packaged and ready for sale. Abba continues to ramp up production towards its goal of between 2,000 and 3,000 kg of dried flower on an annualized basis at its Pickering, Ontario facility. It is now in full perpetual grow with regular harvests every three weeks.

On October 31, 2019, Canada House announced Abba has entered into a five-year supply agreement (the "Supply Agreement") with Pharmadrug Production GmbH ("Pharmadrug"), a German EU GMP approved generic pharmaceutical manufacturer, and a subsidiary of Pharmadrug Inc. (CSE: BUZZ).

Under the Supply Agreement, Pharmadrug will purchase medical cannabis from Abba's cultivation facility for sale in Germany under Pharmadrug's Cannabion brand. Minimum quantities for the first year are 250 kg of dry flower or oil equivalent, with a right to purchase an additional 250 kg, at a bulk sale price of EUR 4.00 per gram. At today's exchange rates, this equates to minimum approximate revenue of \$1.5M CAD during the first year of the Supply Agreement. Minimum quantities for the subsequent years increase to 500 kg of dry flower or oil equivalent, with a right to purchase an additional 500 kg at the same first year price, subject to a price reduction if German wholesale prices fall by more than EUR 1.50 per gram. At the agreed bulk

sale price and today's exchange rates this equates to minimum approximate revenue of \$3.0M CAD during the subsequent years of the Supply Agreement. Subject to a right of first refusal by Pharmadrug, Abba will have the ability to sell additional dry flower or oil equivalent during the term of the Supply Agreement. The parties are also in discussions with respect to importing high CBD/trace THC strains for other Eurozone countries that are CBD-only jurisdictions.

2. Provide a general overview and discussion of the activities of management.

See responses to questions #1, 5 and 10.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

No new products

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None discontinued

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On October 31, 2019, Canada House announced Abba has entered into a five-year supply agreement (the "Supply Agreement") with Pharmadrug Production GmbH ("Pharmadrug"), a German EU GMP approved generic pharmaceutical manufacturer, and a subsidiary of Pharmadrug Inc. (CSE: BUZZ).

Pharmadrug is not related to the Company.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

N/A

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Assets increased as follows:

- **Office Equipment: \$1.5K**
- **Leasehold Improvements: \$33K**
- **New Equipment: \$2.4K**
- **Other: \$2.6K to support clinic operations.**

There were \$1K of disposals related to leasehold improvements, office and other equipment related to a clinic in Newfoundland.

8. Describe the acquisition of new customers or loss of customers.

The active patient account at Canada House Clinics ("CHC") increased by ~2.0% during the month.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

NIL

10. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.

1 hire at Canada House Wellness Group Inc., 1 hire and 1 termination at Canada House Clinics and 1 lay-off at Knalysis Technologies.

11. Report on any labour disputes and resolutions of those disputes if applicable.

N/A

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

No new legal proceedings during the month.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

N/A

14. Provide details of any securities issued and options or warrants granted.

N/A

Security	Number Issued/ (returned to treasury)	Details of Issuance	Use of Proceeds⁽¹⁾

15. Provide details of any loans to or by Related Persons.

Nature of loan	Receivable	Payable	Status
<u>Shareholders or shareholders in common</u> Non-interest bearing, unsecured, and have no specific terms of repayment.	-	\$108,500	

16. Provide details of any changes in directors, officers or committee members.

No changes.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The impact of the new Cannabis Act, provincial responses and activities in relation to the Act and recreational dispensary roll-out strategies continue to evolve. Canada House regularly examines and adjusts its strategy and near-term business focus as changes are announced and in response to market conditions and opportunities.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: November 6, 2019.

Paul L Hart
Name of Director or Senior
Officer

Signed Paul L Hart
Signature

Chief Financial Officer
Official Capacity

Issuer Details		For Month	Date of Report
Name of Issuer Canada House Wellness Group Inc.		Ending October 31, 2019	November 6, 2019
Issuer Address 1773 Bayly Street			
City/Province/Postal Code Pickering, ON L1W 2Y7		Issuer Fax No. (905) 492- 8420	Issuer Telephone No. (844) 696-3349
Contact Name Paul L Hart		Contact Position CFO	Contact Telephone No. (416) 574-4174
Contact Email Address Paul.hart@canadahouse.ca		Web Site Address www.canadahouse.ca	